{"id":3932,"date":"2015-08-20T12:54:09","date_gmt":"2015-08-20T12:54:09","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/"},"modified":"2015-08-20T12:54:09","modified_gmt":"2015-08-20T12:54:09","slug":"delarsrapport-januari-juni-2015","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/delarsrapport-januari-juni-2015\/","title":{"rendered":"Del\u00e5rsrapport januari &#8211; juni \u00a02015"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong>Sammanfattning av rapportperioden 1 januari &#8211; 30 juni 2015<\/strong><\/span><\/p>\n<ul>\n<li><span>Oms\u00e4ttningen uppgick till: 346 KSEK<\/span><\/li>\n<li><span>R\u00f6relseresultatet uppgick till (EBIT): &#8211; 1 344 KSEK <\/span><\/li>\n<li><span>R\u00f6relseresultatet efter skatt uppgick till: &#8211; 1 440 KSEK<\/span><\/li>\n<li><span>Resultat per aktie uppgick till: &#8211; 0,96 SEK<\/span><\/li>\n<\/ul>\n<\/div>\n<p><span><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng <\/strong><\/span><\/p>\n<ul>\n<li><span>Samarbete Nanexa och Uppsala universitet:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>Universitetslektor Denny Mahlin, institutionen f\u00f6r farmaci, Uppsala universitet, har av Uppsala universitet inom programmet &#34;Verifiering f\u00f6r samverkan&#34; erh\u00e5llit bidrag f\u00f6r samverkan med Nanexa.\u00a0Bidraget kommer f\u00f6rst\u00e4rka det redan existerande samarbetet mellan parterna genom att finansiera en halvtidstj\u00e4nst under ett halv\u00e5rs tid f\u00f6r en forskare vid universitetet. Projektet avser unders\u00f6ka hur Nanexas drug delivery-system, PharmaShell\u00ae, kan anv\u00e4ndas f\u00f6r att g\u00f6ra sv\u00e5rl\u00f6sliga l\u00e4kemedel mer l\u00f6sliga och s\u00e5ledes mer biologiskt tillg\u00e4ngliga<\/span><\/li>\n<\/ul>\n<p><span><strong>VD-Kommentar<\/strong><\/span><\/p>\n<p><span>Nanexa har under perioden genomf\u00f6rt ett antal f\u00f6r\u00e4ndringar som ytterligare f\u00f6rst\u00e4rker f\u00f6retagets vidare utveckling. Bland annat har f\u00f6retaget i s\u00e5v\u00e4l styrelse som ledning tagit in f\u00f6rdjupad och bredare kompetens fr\u00e5n l\u00e4kemedelsbranschen vilket blir viktigt b\u00e5de operativt och i kontakter med potentiella partners. <\/span><\/p>\n<p><span>Vi har ocks\u00e5 genomf\u00f6rt listningen p\u00e5 AktieTorget vilket inte bara gett oss kapital att driva verksamheten vidare som planerat utan ocks\u00e5 gett oss en bra plattform f\u00f6r f\u00f6retagets finansiella utveckling. V\u00e5ra samarbetsprojekt l\u00f6per p\u00e5 som planerat b\u00e5de inom v\u00e5rt fokusomr\u00e5de PharmaShell\u00ae och v\u00e5ra \u00f6vriga produktomr\u00e5den. <\/span><\/p>\n<p><span>Jag \u00e4r givetvis v\u00e4ldigt n\u00f6jd \u00f6ver intresset f\u00f6r v\u00e5rt f\u00f6retag under listningsemissionen som n\u00e5dde en teckningsgrad p\u00e5 inte mindre \u00e4n 630%. Tillskottet av pengar g\u00f6r nu att vi kan accelerera utveckling av bolagets drug delivery-system PharmaShell\u00ae som planerat. <\/span><\/p>\n<p><span>Jag ser fram emot en sp\u00e4nnande h\u00f6st med Nanexa och d\u00e5 framf\u00f6r allt med produkt och-aff\u00e4rsutvecklingen av PharmaShell\u00ae.<\/span><\/p>\n<p><span>David Westberg, VD<\/span><\/p>\n<\/p>\n<p><strong><span>Kommentarer till resultatet<\/span><\/strong><br \/><span>Under f\u00f6rsta halv\u00e5ret har Bolaget haft extraordin\u00e4ra utgifter i samband med fusionen av bolagen Nanexa och Candix samt f\u00f6r emissionen och introduktionen p\u00e5 AktieTorget. Sammantaget har dessa kostnader, som \u00e4r av eng\u00e5ngskarakt\u00e4r, summerats till en n\u00e5got h\u00f6gre niv\u00e5 \u00e4n vad vi prognostiserat.<\/span><\/p>\n<p><strong><span>Aktien<\/span><\/strong><br \/><span>Nanexa AB (publ) noterades p\u00e5 Aktietorget den 17 juni, 2015.<\/span><\/p>\n<p><strong><span>Vinst per aktie<\/span><\/strong><span>V<br \/>inst per aktie f\u00f6r Nanexa AB uppgick till -0,96 SEK.<\/span><\/p>\n<p><strong><span>Antalet aktier<\/span><\/strong><br \/><span>Nanexa AB (publ) har per 2015-06-30, 5\u00a0073\u00a0289 stycken aktier med ett kvotv\u00e4rde om 0,13 kr.<\/span><\/p>\n<p><strong><span>Principer f\u00f6r rapportens uppr\u00e4ttande<\/span><\/strong><br \/><span>Del\u00e5rsrapporten har uppr\u00e4ttats enligt samma redovisningsprinciper som i bolagets senaste \u00e5rsredovisning, det vill s\u00e4ga enligt \u00c5rsredovisningslagen och Bokf\u00f6ringsn\u00e4mndens allm\u00e4nna r\u00e5d BFNAR 2012:1 \u00c5rsredovisning och koncernredovisning (K3). Mot bakgrund av fusionen som skedde i april 2015 presenteras de j\u00e4mf\u00f6rande beloppen f\u00f6r 2014 som om bolagen hade konsoliderats. Syftet med detta \u00e4r att ge en mer korrekt bild av bolagets resultat och finansiella st\u00e4llning f\u00f6r perioden jan-juni 2014.<\/span><\/p>\n<p><span><strong>Kommande rapporttillf\u00e4llen<\/strong><br \/>Nanexa AB l\u00e4mnar \u00e5terkommande ekonomisk information enligt f\u00f6ljande plan.<br \/>Bolagets r\u00e4kenskaps\u00e5r \u00e4r 1 januari \u2013 31 december.<\/span><\/p>\n<p><span>Del\u00e5rsrapport Q3 2015:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 19 november, 2015 <\/span><\/p>\n<p><span>Bokslutskommunik\u00e9 2015:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25 februari, 2016<\/span><\/p>\n<p><span>Denna del\u00e5rsrapport har inte varit f\u00f6rem\u00e5l f\u00f6r \u00f6versiktlig granskning av bolagets revisor.<\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/aktietorget.blob.core.windows.net\/press\/news\/nanexa\/74747\/409888.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sammanfattning av rapportperioden 1 januari &#8211; 30 juni 2015<\/p>\n<p>* Oms\u00e4ttningen uppgick till: 346 KSEK<br \/>\n* R\u00f6relseresultatet uppgick till (EBIT): &#8211; 1 344 KSEK<br \/>\n* R\u00f6relseresultatet efter skatt uppgick till: &#8211; 1 440 KSEK<br \/>\n* Resultat per aktie uppgick till: &#8211; 0,96 SEK<\/p>\n","protected":false},"template":"","class_list":["post-3932","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q2_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Del\u00e5rsrapport januari - juni \u00a02015 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport januari - juni \u00a02015 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Sammanfattning av rapportperioden 1 januari - 30 juni 2015 * Oms\u00e4ttningen uppgick till: 346 KSEK * R\u00f6relseresultatet uppgick till (EBIT): - 1 344 KSEK * R\u00f6relseresultatet efter skatt uppgick till: - 1 440 KSEK * Resultat per aktie uppgick till: - 0,96 SEK\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-januari-juni-2015\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-januari-juni-2015\\\/\",\"name\":\"Del\u00e5rsrapport januari - juni \u00a02015 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2015-08-20T12:54:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-januari-juni-2015\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-januari-juni-2015\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-januari-juni-2015\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Del\u00e5rsrapport januari &#8211; juni \u00a02015\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport januari - juni \u00a02015 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/","og_locale":"sv_SE","og_type":"article","og_title":"Del\u00e5rsrapport januari - juni \u00a02015 - Nanexa AB","og_description":"Sammanfattning av rapportperioden 1 januari - 30 juni 2015 * Oms\u00e4ttningen uppgick till: 346 KSEK * R\u00f6relseresultatet uppgick till (EBIT): - 1 344 KSEK * R\u00f6relseresultatet efter skatt uppgick till: - 1 440 KSEK * Resultat per aktie uppgick till: - 0,96 SEK","og_url":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/","url":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/","name":"Del\u00e5rsrapport januari - juni \u00a02015 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2015-08-20T12:54:09+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-januari-juni-2015\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Del\u00e5rsrapport januari &#8211; juni \u00a02015"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}